Kura Oncology (NASDAQ:KURA) Downgraded by Stifel Nicolaus to Hold

Stifel Nicolaus downgraded shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a research note published on Monday, Marketbeat Ratings reports. The brokerage currently has $19.00 target price on the stock, down from their prior target price of $26.00.

Several other equities analysts have also recently issued reports on KURA. HC Wainwright reiterated a buy rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Cantor Fitzgerald restated an overweight rating on shares of Kura Oncology in a report on Monday, September 9th. Wedbush restated an outperform rating and issued a $37.00 price target on shares of Kura Oncology in a report on Friday, August 9th. StockNews.com cut Kura Oncology from a hold rating to a sell rating in a report on Thursday, August 22nd. Finally, JMP Securities restated a market outperform rating and issued a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology has an average rating of Moderate Buy and a consensus price target of $29.20.

Kura Oncology Stock Performance

NASDAQ KURA opened at $18.06 on Monday. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $19.58 and its two-hundred day moving average is $20.27. Kura Oncology has a 12-month low of $7.41 and a 12-month high of $24.17. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of -8.32 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same period last year, the firm posted ($0.53) EPS. The business’s revenue was up .0% on a year-over-year basis. Research analysts expect that Kura Oncology will post -2.45 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP purchased a new stake in Kura Oncology in the 2nd quarter valued at approximately $196,000. Alethea Capital Management LLC lifted its stake in Kura Oncology by 2.4% in the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock valued at $5,475,000 after buying an additional 6,300 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares in the last quarter. AQR Capital Management LLC lifted its stake in Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after buying an additional 58,422 shares in the last quarter. Finally, Armistice Capital LLC lifted its stake in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.